Medicare Part B Step Therapy PD1/PDL1 Products - Non-Small Cell Lung Cancer (NSCLC)
Customize your policy alerts
Sign up for zing_health Policy 6305-D alerts
Get alerted when Policy 6305-D changes without checking for updates manually.
Monitor payer policy activity
This policy governs Medicare Part B coverage of specified PD-1/PD-L1 products for non-small cell lung cancer (NSCLC). Libtayo is preferred, while non-preferred products require prior authorization and an approved clinical exception for members new to non-preferred treatment.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.